Distinct but complementary contributions of PPAR isotypes to energy homeostasis

被引：314
作者：
Dubois, Vanessa [1 ,2 ]
Eeckhoute, Jerome [1 ,2 ]
Lefebvre, Philippe [1 ,2 ]
Staels, Bart [1 ,2 ]
机构：
[1] Univ Lille, CHU Lille, INSERM, Inst Pasteur Lille, U1011 EGID, Lille, France
[2] Inst Pasteur, 1 Rue Prof Calmette, F-59019 Lille, France
来源：
JOURNAL OF CLINICAL INVESTIGATION | 2017年 / 127卷 / 04期
关键词：
PROLIFERATOR-ACTIVATED-RECEPTOR; CORONARY-HEART-DISEASE; FATTY LIVER-DISEASE; SINGLE NUCLEOTIDE POLYMORPHISMS; TYPE-2; DIABETES-MELLITUS; T-REG CELLS; DENSITY-LIPOPROTEIN-CHOLESTEROL; IMPROVES INSULIN SENSITIVITY; RANDOMIZED CONTROLLED-TRIAL; IMPAIRED GLUCOSE-TOLERANCE;
D O I：
10.1172/JCI88894
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Peroxisome proliferator-activated receptors (PPARs) regulate energy metabolism and hence are therapeutic targets in metabolic diseases such as type 2 diabetes and non-alcoholic fatty liver disease. While they share anti-inflammatory activities, the PPAR isotypes distinguish themselves by differential actions on lipid and glucose homeostasis. In this Review we discuss the complementary and distinct metabolic effects of the PPAR isotypes together with the underlying cellular and molecular mechanisms, as well as the synthetic PPAR ligands that are used in the clinic or under development. We highlight the potential of new PPAR ligands with improved efficacy and safety profiles in the treatment of complex metabolic disorders.
引用
收藏
页码：1202 / 1214
页数：13
相关论文
共 193 条
[11]   MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin [J].
Bays, Harold E. ;
Schwartz, Sherwyn ;
Littlejohn, Thomas, III ;
Kerzner, Boris ;
Krauss, Ronald M. ;
Karpf, David B. ;
Choi, Yun-Jung ;
Wang, Xueyan ;
Naim, Sue ;
Roberts, Brian K. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (09) :2889-2897
[12]   A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis [J].
Belfort, Renata ;
Harrison, Stephen A. ;
Brown, Kenneth ;
Darland, Celia ;
Finch, Joan ;
Hardies, Jean ;
Balas, Bogdan ;
Gastaldelli, Amalia ;
Tio, Fermin ;
Pulcini, Joseph ;
Berria, Rachele ;
Ma, Jennie Z. ;
Dwivedi, Sunil ;
Havranek, Russell ;
Fincke, Chris ;
DeFronzo, Ralph ;
Bannayan, George A. ;
Schenker, Steven ;
Cusi, Kenneth .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (22) :2297-2307
[13]   HEPATIC PEROXISOME PROLIFERATION IN RODENTS AND ITS SIGNIFICANCE FOR HUMANS [J].
BENTLEY, P ;
CALDER, I ;
ELCOMBE, C ;
GRASSO, P ;
STRINGER, D ;
WIEGAND, HJ .
FOOD AND CHEMICAL TOXICOLOGY, 1993, 31 (11) :857-907
[14]   PPAR-ATGL pathway improves muscle mitochondrial metabolism: implication in aging [J].
Biswas, Dipsikha ;
Ghosh, Mainak ;
Kumar, Subhankar ;
Chakrabarti, Partha .
FASEB JOURNAL, 2016, 30 (11) :3822-3834
[15]   The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial [J].
Black, R. Neil A. ;
Ennis, Cieran N. ;
Young, Ian S. ;
Hunter, Steven J. ;
Atkinson, A. Brew ;
Bell, Patrick M. .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2014, 28 (03) :323-327
[16]   PPARδ activation attenuates hepatic steatosis in Ldlr-/- mice by enhanced fat oxidation, reduced lipogenesis, and improved insulin sensitivity [J].
Bojic, Lazar A. ;
Telford, Dawn E. ;
Fullerton, Morgan D. ;
Ford, Rebecca J. ;
Sutherland, Brian G. ;
Edwards, Jane Y. ;
Sawyez, Cynthia G. ;
Gros, Robert ;
Kemp, Bruce E. ;
Steinberg, Gregory R. ;
Huff, Murray W. .
JOURNAL OF LIPID RESEARCH, 2014, 55 (07) :1254-1266
[17]   Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience [J].
Bonds, D. E. ;
Craven, T. E. ;
Buse, J. ;
Crouse, J. R. ;
Cuddihy, R. ;
Elam, M. ;
Ginsberg, H. N. ;
Kirchner, K. ;
Marcovina, S. ;
Mychaleckyj, J. C. ;
O'Connor, P. J. ;
Sperl-Hillen, J. -A. .
DIABETOLOGIA, 2012, 55 (06) :1641-1650
[18]   Role of Adiponectin in Coronary Heart Disease Risk A Mendelian Randomization Study [J].
Borges, Maria Carolina ;
Lawlor, Debbie A. ;
de Oliveira, Cesar ;
White, Jon ;
Horta, Bernardo Lessa ;
Barros, Aluisio J. D. .
CIRCULATION RESEARCH, 2016, 119 (03) :491-+
[19]   PPARα blocks glucocorticoid receptor α-mediated transactivation but cooperates with the activated glucocorticoid receptor α for transrepression on NF-κB [J].
Bougarne, Nadia ;
Paumelle, Rejane ;
Caron, Sandrine ;
Hennuyer, Nathalie ;
Mansouri, Roxane ;
Gervois, Philippe ;
Staels, Bart ;
Haegeman, Guy ;
De Bosscher, Karolien .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (18) :7397-7402
[20]   PPARγ activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties [J].
Bouhlel, M. Amine ;
Derudas, Bruno ;
Rigamonti, Elena ;
Dievart, Rebecca ;
Brozek, John ;
Haulon, Stephan ;
Zawadzki, Christophe ;
Jude, Brigitte ;
Torpier, Gerard ;
Marx, Nikolaus ;
Staels, Bart ;
Chinetti-Gbaguidi, Giulia .
CELL METABOLISM, 2007, 6 (02) :137-143
12345678910